Early data hint at sub-blockbuster add-on for Alexion's billion dollar antibody
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals has presented positive data from a Phase II single-arm study of its blockbuster Soliris (eculizumab) in a new potential indication, the prevention of antibody-mediated rejection (AMR), a severe and life-threatening complication in certain patients undergoing kidney transplantation. If the preliminary study findings are confirmed – they indicate that around 20% of kidney used in transplants might not be wasted through organ rejection - Alexion’s antibody could take a reasonable share in a $1.4bn market for kidney sparing in transplantation.